ACM
ABBV icon

Accent Capital Management’s AbbVie ABBV Stock Holding History

Accent Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,500
Closed -$296K – 190
2024
Q3 		$296K Hold
1,500
– – 0.17% 52
2024
Q2 		$257K Hold
1,500
– – 0.16% 49
2024
Q1 		$273K Sell
1,500
-2,000
-57% -$345K 0.24% 39
2023
Q4 		$542K Buy
+3,500
New +$510K 0.43% 38

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Accent Capital Management's ABBV Position: Q4 2024 in Review

Accent Capital Management sold out of AbbVie (ABBV) in Q4 2024, closing a stake of 1,500 shares — an estimated $296K sold.

Accent Capital Management first reported a position in ABBV in Q4 2023 and held it in 4 quarters. The position peaked at $542K in Q4 2023. 3,744 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

  • Accent Capital Management reported no remaining AbbVie position as of Q4 2024 after selling out during the quarter.
  • Accent Capital Management sold 1,500 AbbVie shares in Q4 2024, an estimated $296K.
  • Accent Capital Management first reported a position in AbbVie in Q4 2023 and held it in 4 quarters.
  • Accent Capital Management's AbbVie position peaked at $542K in Q4 2023.
  • 3,744 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Accent Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.